A class action lawsuit has been filed against Unicycive Therapeutics and some of its officers for allegedly making false and misleading statements about the compliance of a third-party manufacturing vendor. The complaint claims Unicycive did not properly inspect or audit the vendor's facility, which may delay FDA approval of their drug oxylanthanum carbonate. Investors who bought Unicycive securities between December 29, 2025, and June 29, 2026, are encouraged to join the lawsuit. The law firm Bronstein, Gewirtz & Grossman is representing the investors on a contingency basis, with a deadline to request lead plaintiff status by November 2, 2026.
Bitcoin's market capitalization has reached approximately 1.7% of the global money basket, which totals around $138 trillion combining global fiat M2 money supply and gold's market cap. This milestone highlights Bitcoin's growing role as an alternati...
After 16 years of dormancy, 600 Bitcoin mined in March 2010 were transferred to new addresses, valued at about $48 million. Blockchain analysts Whale Alert and Lookonchain confirmed the coins are not linked to Bitcoin's creator, Satoshi Nakamoto, des...
Cryptocurrency markets display varied price changes with Bitcoin trading slightly down at $79,687 and Ethereum up by 0.87% at $2,481.48. Notable surges include ARB rising 39.29% and RAY soaring 60.91%, indicating strong interest in these tokens. Othe...
Bitcoin reached a four-month high of $81,500 before consolidating, supported by $3.5 billion in August spot Bitcoin ETF inflows and $731 million on Sept. 3 alone. Bond market stress resumed with yields hitting 20-year highs, fueling a narrative of in...
Preferred stock and baby bond markets remain stable with tight credit spreads, but yields have increased due to rising long-term interest rates. A key court ruling supports fixed coupons on LIBOR-based preferreds after LIBOR ended, benefiting fixed-r...
